Ag Biotech Summit set for Nov. 18-19 in Raleigh

Posted by on Sep 21, 2014 in Newsroom | 0 comments

RALEIGH, N.C. – Food and agricultural experts from around the nation will join North Carolina peers at the McKimmon Conference Center in Raleigh Nov. 18 and 19 for a wide-ranging discussion of technologies and policies affecting food production. A collaborative effort of North Carolina State University’s College of Agriculture and Life Sciences (CALS) and the North Carolina Biotechnology Center’s AgBiotech Initiative, the North Carolina Agriculture & Biotechnology Summit will explore the state’s growing global leadership in agricultural biotechnology, and the associated...

Read More

University of Florida incubator gets national economic development recognition

Posted by on Sep 21, 2014 in Newsroom | 0 comments

GAINESVILLE, FL. – The University of Florida’s Sid Martin Biotechnology Incubator – one of the country’s first bio-business incubators – has received a national award, recognizing it as a model for economic growth. The State Science & Technology Institute recognized the incubator along with four others across the country for its success in tech-based economic development. The 40,000-square-foot incubator was created in 1995 to help commercialize UF’s life science research and create a bioscience industry in the town of Alachua. Since then, SSTI said,...

Read More

Parion receives $3M to work on cystic fibrosis treatment

Posted by on Sep 18, 2014 in Newsroom | 0 comments

DURHAM, N.C. – Durham drug developer Parion Sciences  received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) to continue work on its investigational treatment for cystic fibrosis (CF). This grant will speed up the timeline for a Phase 2 trial in which Parion will test its experimental drug, called P-1037, in patents with CF. Parion now hopes to begin enrolling patients in early 2015. Parion scientists designed P-1037 – an Epithelial sodium channel (ENaC) inhibitor – to block sodium channels on the airway surfaces. In pulmonary diseases where there is a build-up...

Read More

Clearside Biomedical, Inc. Completes $16 Million Series B Financing

Posted by on Sep 17, 2014 in Newsroom | 0 comments

ALPHARETTA, GA. – Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund. Clearside expects to use proceeds from this financing to fund continued development of Clearside’s proprietary suprachoroidal space (SCS) drug administration and advance its CLS-1001 and CLS-1003 programs into Phase 2 trials by the end of 2014. About Clearside...

Read More

UF OTL Director David Day to Dye Hair Orange and Blue to Celebrate Licensing Record

Posted by on Sep 10, 2014 in Newsroom | 0 comments

GAINESVILLE, FL. – Last year, the Office of Technology Licensing was off to a slow start finding commercial partners to license patented research discoveries generated at UF. To inspire his staff to achieve their targeted numbers, UF Assistant Vice President David Day made a promise he thought he’d never have to keep: If OTL signed more than 85 licenses and options, he would dye his hair whatever color staff chose. Well, the incentive worked. The OTL staff not only achieved but exceeded their goal, signing a record 87 licenses and options for the fiscal year ending June 30. The...

Read More

Cempra Milestone Highlights Experimental Antibiotic’s Potential

Posted by on Sep 10, 2014 in Newsroom | 0 comments

CHAPEL HILL, N.C. – Cempra Pharmaceuticals’ efforts to bring patients a next-generation antibiotic that could help address drug-resistant bacteria now has a boost from Japan. The company last year licensed Japanese development and commercialization rights for its solithromycin to Toyama Chemical Co. in a deal that could pay up to $60 million in milestones. Cempra now says Toyama completed Phase 1 trials of the antibiotic and received the regulatory go ahead to start Phase 2 trials, a milestone that triggers a $10 million payment to Cempra. Toyama is currently testing solithromycin...

Read More